Cato Daily Podcast podcast

Future MDMA Treatment Following FDA's Rejection

0:00
24:10
Rewind 15 seconds
Fast Forward 15 seconds
The FDA's rejection of MDMA as a treatment may well be a short-term setback for legally helping people with PTSD and other disorders. Mason Marks of Harvard Law School’s Petrie-Flom Center for Health Law Policy offers his assessment.

Hosted on Acast. See acast.com/privacy for more information.

More episodes from "Cato Daily Podcast"